Abstracts tagged "treat to target"

Abstract Number: 0282 • ACR Convergence 2021
5-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients Who Received Treat-to-Target Management: A Population-based Cohort Study
Tsz On Lam¹ and Lai-Shan Tam², ¹Prince of Wales Hospital, Hong Kong, Hong Kong, ²Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is associated with higher cardiovascular disease (CVD) risk due to the underlying inflammation.It is uncertain if the excess CV risk could…
Abstract Number: 0803 • ACR Convergence 2021
Rheumatoid Arthritis Practice Performance (RAPP) Project at 6 Years: Population Medicine (POPMED) Principles and Treat to Target (T2T) Care Yield Dramatic Improvements in Both Outcomes and Access for RA Patients and Productivity for Rheumatologists
William Arnold¹, Erin Arnold¹, David Sikes², Gary Crump³, Kathleen Thomas⁴ and andrew johnson⁵, ¹Arnold Arthritis and Rheumatology, Wilmette, IL, ²Florida Medical Clinic, Wesley Chapel, FL, ³Rheumatology Associates, Louisville, KY, ⁴Community Health Network, Noblesville, IN, ⁵PopMed Solutions, Boyds, MD
Background/Purpose: The RAPP quality improvement project is a voluntary consortium of practicing rheumatologists founded in 2013 by Timothy Harrington MD, MACR. The primary focus is…
Abstract Number: 1895 • ACR Convergence 2021
Achievement of Target Serum Uric Acid Among Gout Patients Treated with Long-term Urate Lowering Therapy in the ACR’s Rheumatology Informatics System for Effectiveness (RISE) Registry
Nevin Hammam, Jing Li, Julia L Kay, Jinoos Yazdany and Gabriela Schmajuk, University of California San Francisco, San Francisco, CA
Background/Purpose: The American College of Rheumatology’s (ACR) 2012 guidelines for the management of gout recommend using a treat-to-target (T2T) approach to lower serum uric acid…
Abstract Number: 255 • 2019 ACR/ARP Annual Meeting
Designing and Testing Treat to Target as a New Care Model in JIA Across a Network of Pediatric Rheumatology Centers
Esi Morgan¹, Janalee Taylor ², Tingting Qiu ³, Nancy Griffin ², Anne Paul ², Catherine Bingham ⁴, Danielle Bullock ⁵, Kerry Ferraro ⁶, Y Goh ⁷, Mileka Gilbert ⁸, Olha Halyabar ⁹, Karla Jones ¹⁰, Melanie Kohlheim ¹¹, Daniel J. Lovell ¹², Darby MacDonald ¹⁰, Emily Smitherman ¹³, Anjie Vago ¹⁴, Jennifer Weiss ¹⁵, Cagri Yildirim-Toruner ¹⁰, Angela Young ¹⁶, Michelle Batthish ¹⁷, Beth Gottlieb ¹⁸, Julia Harris ¹⁹, Melissa Hazen ²⁰, Ronald Laxer ⁷, Tzielan Lee ²¹, Melissa Mannion ²², Judyann Olson ²³, MIchael Shishov ²⁴, Sheetal Vora ²⁵ and Jonathan Burnham ²⁶, ¹Cincinnati Children’s Hospital, University of Cincinnati, Cinncinati, OH, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Penn State Hershey Children's, Hershey, ⁵University of Minnesota, Minneapolis, MN, ⁶PR-CON Parent Working Group, Fort Washington, PA, ⁷Hospital for Sick Children, Toronto, ON, Canada, ⁸Medical Univeristy of South Carolina, Charleston, SC, ⁹Boston Children's Hospital, Boston, ¹⁰Nationwide Children's Hospital, Columbus, OH, ¹¹PR-COIN Parent Working Group, Columbus, OH, ¹²Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ¹³University of Alabama at Birmingham, Birmingham, AL, ¹⁴PR-COIN Parent Working Group, Hershey, PA, ¹⁵Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁶PR-COIN Parent Working Group, Lexington, KY, ¹⁷McMaster University, Hamilton, Canada, ¹⁸Cohen Children's Hospital, New Hyde Park, NY, ¹⁹Children's Mercy Hospital, Kansas City, MO, ²⁰Boston Children's Hospital, Boston, MA, ²¹Stanford University School of Medicine, Palo Alto, ²²Children's of Alabama, Birmingham, ²³Medical College of WIsconsin, Milwaukee, WI, ²⁴Phoenix Children's, Phoenix, AZ, ²⁵Levine Children's, Charlotte, NC, ²⁶The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: In 2018 an international task force published a recommended Treat to Target (T2T) approach to juvenile idiopathic arthritis (JIA) treatment. In February 2019, 17…
Abstract Number: 2389 • 2019 ACR/ARP Annual Meeting
Treat to Target by Specific Cytokine Interdiction: Multiple Biomarker Disease Activity Test Deconstructed
L Douglas Graham ¹ and Lee Graham¹, ¹Du Page Medical Group, Westmont, IL
Background/Purpose: Rheumatologists have been encouraged to achieve low disease activity state when treating rheumatoid arthritis (RA). If it cannot be achieved with initial therapy, experts…
Abstract Number: 2832 • 2019 ACR/ARP Annual Meeting
Using a Learning Collaborative to Develop an RA Disease Activity Communication Tool to Promote Shared Decision-Making in Treat to Target
Lucy Liu¹, Sonam Choden ², Jennifer Barton ³, Puneet Bajaj ⁴, Christie Bartels ⁵, Maria Danila ⁶, Elizabeth Wahl ⁷, Kimberly Reiter ⁸, Joann Zell ⁹, Christina Downey, MD ¹⁰, Elena Weinstein ¹¹, Gabriela Schmajuk ² and Jinoos Yazdany ¹², ¹UCSF, Oakland, CA, ²UCSF, SFVAMC Division of Rheumatology, San Francisco, CA, ³VA Portland Health Care System & Oregon Health & Science University, Portland, OR, ⁴UT Southwestern, Dallas, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷VA Puget Sound, Seattle, WA, ⁸Albuquerque VA Medical Center, University of NM School of Medicine, Albuquerque, NM, ⁹Denver Health, Denver, CO, ¹⁰Loma Linda University Medical Center, Loma LInda, CA, ¹¹University of Colorado Department of Rheumatology, Denver, CO, ¹²UCSF Division of Rheumatology, San Francisco, CA
Background/Purpose: A treat to target (T2T) approach in managing RA can improve patient outcomes. A key component to T2T is establishing personalized treatment targets through…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].